Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 1,870

Hikma Pharmaceuticals (LON:HIK) had its target price lifted by Jefferies Financial Group from GBX 1,850 to GBX 1,870 in a report released on Tuesday,Digital Look reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 29.77% from the company’s previous close.

HIK has been the topic of a number of other reports. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,800 target price on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average target price of GBX 2,128.

Hikma Pharmaceuticals Stock Up 2.3%

Shares of HIK stock opened at GBX 1,441 on Tuesday. The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82. The firm’s 50-day moving average is GBX 1,322.61 and its 200-day moving average is GBX 1,500.84. The stock has a market cap of £3.12 billion, a price-to-earnings ratio of 7.96, a PEG ratio of 2.38 and a beta of 0.61. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 2,164.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.